,,this investment is proving out to be some painful these days as we drip off market cap for what has been many weeks now. It would seem to any investor on the sidelines that dead money awaits them if they invest here due to most likely considerable dilution coming. The next news around financing or the plan going forward will certainly be associated to this double digit share price whether it be with or without a partner or agreement or other arrangement of some sort. Since the failed BoM I see at least another 2 years lost to, finding a partner, planning the future and being able to create more concrete data to support our epigenetic science. If we actually do create such data. That is my minimum time line from what we have witnessed past.

Possibly, if ZCC gets the nod,,and that is an if,,one would think we would have a sympathetic reaction to share price. Until then it is very clear the Market does not see apabetalone as being any kind of a blockbusting drug.

It will be very surprising if RVX management will be able to sell their theoretical value within any kind of financing arrangment to carry us forward. The art of any deal from a partnering perspective would certainly relate the market pricing at the time. Its just down right plain painful!

This is slowly becoming my opinion based on Market activity as of late,,due in part to,, Management not having specifics to comfort its shareholders.